Ex-SAC Manager Martoma Indictment May Mean No Plea Talks
Mathew Martoma, the former SAC Capital Advisors LP portfolio manager accused in what prosecutors have called the biggest insider-trading case in history, was indicted, a sign that he may not be considering a plea deal.
Martoma, 38, was accused today of using illegal tips on testing of an Alzheimer’s disease drug to help SAC, the hedge fund founded by Steven A. Cohen, to profit by $276 million from trading in shares of Elan Corp. (ELN) and Wyeth LLC. He was arrested at his Boca Raton, Florida, home on Nov. 20 and originally charged in a criminal complaint.
Prosecutors faced a Dec. 26 deadline to indict Martoma or ask the court for more time. Today’s move shows the government is turning up the heat in its efforts to get Martoma to cooperate with its investigation of SAC, according to Anthony Sabino, who teaches law at St. John’s University in New York.
“This is telling Martoma: You don’t want to deal with us? Fine,” Sabino said. “You’re going to go up the river by yourself, so think about that over Christmas.”
If convicted, Martoma faces as many as 20 years in prison on the securities fraud charges and five years on the conspiracy charge.
“Though disappointing, today’s events come as no surprise,” Martoma’s lawyer, Charles Stillman, said in a statement. “The simple fact is that Mathew Martoma did not trade on inside information, is innocent of all these charges and we look forward to his ultimate vindication.”
As in the criminal complaint, the 12-page indictment alleges Martoma used the illegal tips to advise an unnamed “hedge fund owner” to trade in the shares of Elan and Wyeth. A person familiar with the case identified Cohen as the fund owner last month.
Prosecutors said Martoma and the hedge fund owner spoke on the phone for 20 minutes on July 20, 2008, the day before SAC started dumping its Wyeth and Elan stock. Martoma’s testimony about that telephone call and other contacts with Cohen concerning Wyeth and Elan would be key to any attempt to prosecute Cohen.
Jonathan Gasthalter, a spokesman for Stamford, Connecticut- based SAC, declined to comment on the indictment. Gasthalter has said Cohen and SAC acted appropriately in making the trades. Cohen hasn’t been charged criminally or sued by regulators in the case.
Martoma rejected several bids by prosecutors for his cooperation, according to a person familiar with the case. When first confronted by an FBI agent in the front yard of his mansion last year, he fainted, another person said.
“It’s another step on the government’s march into Cohen’s office,” Erik Gordon, a professor at the University of Michigan Law School and Ross School of Business, said in an e-mail after the indictment. “Given the prosecutors’ success in getting convictions and serious jail sentences, it’s time for anyone at SAC who is connected with insider trading to start having nightmares.”
The case is assigned to U.S. District Judge Paul Gardephe, a former federal prosecutor and in-house lawyer for Time Warner Inc. He was appointed by President George W. Bush and took the bench in 2008.
Martoma worked as a portfolio manager for CR Intrinsic Investors in Stamford, Connecticut, a unit of SAC Capital. The indictment claims that from sometime in 2006 until July 29, 2008, he participated in a scheme to get inside information about clinical trials of bapineuzumab, or bapi, a drug intended to treat Alzheimer’s disease. Martoma got the tips from an unnamed cooperating witness, according to the indictment.
A complaint filed last month by the U.S. Securities and Exchange Commission identified the cooperating witness as Dr. Sid Gilman, a University of Michigan neurologist who was head of the safety monitoring committee for the drug trial. Martoma had 42 paid consultations with Gilman through an expert networking firm, according to the government. Gilman worked with Gerson Lehrman Group, according to his curriculum vitae.
Gilman, 80, has entered into a non-prosecution agreement and is cooperating with prosecutors.
At the beginning of the relationship, the doctor passed along generally positive safety data about the trial, according to the government. Martoma allegedly bought shares of Elan and Wyeth for his portfolio. The hedge fund owner also bought Elan and Wyeth, based on Martoma’s recommendation, prosecutors said.
In mid-July 2008, the doctor passed Martoma secret data showing that bapi failed to halt progression of Alzheimer’s in patients in the clinical test, the U.S. said. The hedge fund owner, at Martoma’s recommendation, sold off almost all of the fund’s $700 million position in Elan and Wyeth, then sold the stock short, prosecutors claimed.
When the clinical trial results became public, shares in both companies plunged, allowing the hedge fund to make $276 million in profits and losses avoided, according to the government. Martoma received a $9.3 million bonus as a result, according to the indictment.
To contact the reporters on this story: Bob Van Voris in Manhattan federal court, at firstname.lastname@example.org.
To contact the editor responsible for this story: Michael Hytha at email@example.com
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.